Show simple item record

dc.contributor.authorKlug, Dana M
dc.contributor.authorIdiris, Fahima I M
dc.contributor.authorBlaskovich, Mark A T
dc.contributor.authorvon Delft, Frank
dc.contributor.authorDowson, Christopher G
dc.contributor.authorKirchhelle, Claas
dc.contributor.authorRoberts, Adam P
dc.contributor.authorSinger, Andrew C
dc.contributor.authorTodd, Matthew H
dc.date.accessioned2022-02-04T09:26:44Z
dc.date.available2022-02-04T09:26:44Z
dc.date.issued2021-06-11
dc.identifier.issn2398-502X
dc.identifier.pmid34250265
dc.identifier.doi10.12688/wellcomeopenres.16847.1
dc.identifier.urihttp://hdl.handle.net/10147/631307
dc.descriptionThere is an increasingly urgent need for new antibiotics, yet there is a significant and persistent economic problem when it comes to developing such medicines. The problem stems from the perceived need for a "market" to drive commercial antibiotic development. In this article, we explore abandoning the market as a prerequisite for successful antibiotic research and development. Once one stops trying to fix a market model that has stopped functioning, one is free to carry out research and development (R&D) in ways that are more openly collaborative, a mechanism that has been demonstrably effective for the R&D underpinning the response to the COVID pandemic. New "open source" research models have great potential for the development of medicines for areas of public health where the traditional profit-driven model struggles to deliver. New financial initiatives, including major push/pull incentives, aimed at fixing the broken antibiotics market provide one possible means for funding an openly collaborative approach to drug development. We argue that now is therefore the time to evaluate, at scale, whether such methods can deliver new medicines through to patients, in a timely manner.en_US
dc.language.isoenen_US
dc.rightsCopyright: © 2021 Klug DM et al.
dc.subjectAMRen_US
dc.subjectANTIBIOTICSen_US
dc.subjectdrug developmenten_US
dc.subjectdrug discoveryen_US
dc.subjectEconomicsen_US
dc.subjectincentivesen_US
dc.subjectopen scienceen_US
dc.subjectpolicyen_US
dc.titleThere is no market for new antibiotics: this allows an open approach to research and development.en_US
dc.typeArticleen_US
dc.identifier.journalWellcome open researchen_US
dc.source.journaltitleWellcome open research
dc.source.volume6
dc.source.beginpage146
dc.source.endpage
refterms.dateFOA2022-02-04T09:26:45Z
dc.source.countryUnited Kingdom
dc.source.countryEngland


Files in this item

Thumbnail
Name:
wellcomeopenres-6-18582.pdf
Size:
645.6Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record